Insulet (NASDAQ:PODD) will post its quarterly earnings results after the market closes on Wednesday, February 21st. Analysts expect Insulet to post earnings of ($0.08) per share for the quarter.
Insulet (NASDAQ PODD) opened at $76.73 on Tuesday. Insulet has a 12 month low of $38.43 and a 12 month high of $78.65. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65. The stock has a market cap of $4,464.75, a P/E ratio of -153.46 and a beta of 1.59.
A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Insulet from a “sell” rating to a “hold” rating in a research note on Thursday, February 1st. BidaskClub upgraded shares of Insulet from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Raymond James Financial upgraded shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research report on Monday, January 8th. UBS Group upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday, January 8th. Finally, Barclays restated a “buy” rating and set a $78.00 price objective on shares of Insulet in a research report on Wednesday, December 13th. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $62.53.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.